<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00738829</url>
  </required_header>
  <id_info>
    <org_study_id>CLL-5</org_study_id>
    <secondary_id>EudraCT Nr. 2008-001430-27</secondary_id>
    <secondary_id>ML21718</secondary_id>
    <nct_id>NCT00738829</nct_id>
  </id_info>
  <brief_title>Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL</brief_title>
  <official_title>Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL) - a Dose-finding Study With Concomitant Evaluation of Safety and Efficacy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbeitsgemeinschaft medikamentoese Tumortherapie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Arbeitsgemeinschaft medikamentoese Tumortherapie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the maximal tolerated dose level of lenalidomide
      combined with fludarabine/rituximab in the therapy of patients with previously untreated
      CD20-positive chronic lymphocytic leukemia. Following a dose escalation phase lenalidomide
      will be given at the pre-determined maximum tolerated dose in combination with rituximab to
      further determine the efficacy and tolerability of this regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-randomized, multicenter, open-label, single-arm Phase I/II study in patients
      with previously untreated CD20-positive CLL. Phase I of the study will evaluate the maximal
      tolerated lenalidomide dose level in combination with fludarabine/rituximab
      chemoimmunotherapy in 10 patients. Phase II will determine efficacy using the combination in
      the previously defined maximal tolerated dose. Both phases will be followed by a maintenance
      phase evaluating the tolerability and possibility to further improve response quality.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lenalidomide Maximum Tolerated Dose</measure>
    <time_frame>Dose escalation stage</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profile of Lenalidomide/Fludarabine/Rituximab treatment</measure>
    <time_frame>Study Duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Profile of Lenalidomide/Rituximab</measure>
    <time_frame>Study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate for Lenalidomide/Fludarabine/Rituximab combination treatment</measure>
    <time_frame>Dose escalation stage</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate for Lenalidomide/Rituximab combination therapy</measure>
    <time_frame>Study Duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate by 4-colour flow cytometric MRD analysis</measure>
    <time_frame>Study Duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of Life scores</measure>
    <time_frame>Study Duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors and clonal evolution</measure>
    <time_frame>Study Duration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Leukemia, Lymphocytic, Chronic, B-Cell</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenalidomide Dose Escalation combined with Fludarabine/Rituximab followed by maximum tolerated lenalidomide dose/Rituximab maintenance therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Dose escalation stage: starting dose 2.5mg/d, dose escalation via 5/10/15/20/25 mg/d every 28 days if no dose-limiting toxicity.
During maintenance stage dosing on days 1-28 for max. 6 months at maximum tolerated dose reached during dose escalation stage.</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>25 mg/m2 i.v. d1-3 or 40 mg/m2 po d1-3 every 28 days for 6 cycles during dose escalation stage.</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Fludarabine phosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Dose escalation stage: 375 mg/m2 i.v. d4 Cycle 1, 500 mg/m2 i.v. d1 Cycles 2-6.
Maintenance stage: 375 mg/m2 i.v. at 2/4/6 months after end of escalation stage.</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>MabThera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  B-CLL (CD23+, CD5+, CD19+, CD20+)

          -  Treatment indication according to NCI criteria

          -  Age &gt;= 18 yrs

          -  No previous treatment of CLL by chemo-, radio- or immunotherapy

          -  Life expectancy &gt; 6 months

          -  Written informed consent

          -  Women of non-childbearing potential or women of childbearing potential and men using
             effective contraception

        Exclusion Criteria:

          -  Active bacterial, viral or fungal infection

          -  Positivity for HIV, Hepatitis B or C

          -  Reduce organ functions and bone marrow dysfunction not due to CLL

          -  Creatinine clearance below 30 ml/min

          -  Patients with medical conditions requiring long-term use of systemic corticosteroids
             during study treatment

          -  Patients with a history of severe cardiac disease

          -  Other known co-morbidity with the potential to dominate survival

          -  Transformation to aggressive B-cell malignancy

          -  Known hypersensitivity to humanised monoclonal antibodies or any of the study drugs

          -  Pregnant or breast-feeding women

          -  Any co-existing medical or psychological condition that would preclude participation
             in the study or compromise ability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Greil, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaetsklinik f. Innere Medizin III, Universitaetsklinikum der PMU, Salzburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Universitaet Innsbruck, Abtlg. f. Haematologie und Onkologie</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Feldkirch</name>
      <address>
        <city>Feldkirch</city>
        <zip>A-6806</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus d. Barmherzigen Schwestern Linz</name>
      <address>
        <city>Linz</city>
        <zip>A-4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Elisabethinen Linz GmbH</name>
      <address>
        <city>Linz</city>
        <zip>A-4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Stadt Linz</name>
      <address>
        <city>Linz</city>
        <zip>A-4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik f. Innere Medizin III</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen GmbH</name>
      <address>
        <city>Wels</city>
        <zip>A-4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2008</study_first_submitted>
  <study_first_submitted_qc>August 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2008</study_first_posted>
  <last_update_submitted>August 29, 2013</last_update_submitted>
  <last_update_submitted_qc>August 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CLL</keyword>
  <keyword>untreated</keyword>
  <keyword>immune therapy</keyword>
  <keyword>dose escalation</keyword>
  <keyword>maximum tolerated dose</keyword>
  <keyword>maintenance therapy</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Fludarabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

